The notion of CHF course stability: Is it acceptable for Russian practice?

Aim. To evaluate preparedness of physicians in real clinical practice to strive for stabilizing the course of CHF by control of clinical and hemodynamic indexes both in prevention of admission for decompensated CHF and following discharge from the hospital. Materials and methods. The study included 750 CHF patients with any NYHA FC who were admitted in emergency for decompensated CHF. All patients with CHF were followed up for a year after discharge from the hospital. Medical records of inpatients (MRIP) and outpatients (MROP) were analyzed including determination of clinical symptoms and administered doses of medicines. Changes in clinical parameters during a year were recorded. Results. CHF decompensation was evident as pulmonary edema in 1.6% of cases and acute left ventricular failure in 18.5% of cases. All the rest of decompensated CHF cases included ascites or hyposarca (21.1%), or increased edema syndrome with unstable hemodynamics (58.5%). In MROPs, weight control was presented for 1.2% of patients. The composite index of effectively achieved control of hemodynamics and body weight was only 0.2%. Treatment effectiveness decreases due to absence of drug titration and switching therapies, which considerably impairs prognosis for patients. Conclusion. Outpatient physicians lack alertness for development of CHF decompensation, and control of hemodynamics and body weight of patients remains ineffective. Physicians are not prepared to achieve recommended doses of medicines, which provokes high risk of fatal outcome and/or rehospitalization.

ХСН, декомпенсация ХСН, стабильное течение СН, chronic heart failure, decompensated CHF, stable course of heart failure

1. Gheorghiade M., De Luca L., Fonarow G.C., Filippatos G., Metra M., Francis G.S. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol. 2005; 96 (6A): 11G - 17G.

2. Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П., Коротеев А.В., Мареев Ю.В., Овчинников А.Г. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Утверждены на Конгрессе ОССН 7 декабря 2012 года, на Правлении ОССН 31 марта 2013 и Конгрессе РКО 25 сентября 2013 года. Журнал Сердечная Недостаточность. 2013; 14 (7): 379-472.

3. Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J.G.F., Coats A.J.S. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016; 37 (27): 2129-200. DOI: 10.1093/eurheartj/ehw128

4. WRITING COMMITTEE MEMBERS, Yancy C.W., Jessup M., Bozkurt B., Butler J., Casey D.E. et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 128 (16): e240-327. DOI: 10.1161/CIR.0b013e31829e8776

5. The Consensus Trial Study Group. Effects of Enalapril on Mortality in Severe Congestive Heart Failure. New England Journal of Medicine. 1987; 316 (23): 1429-35. DOI: 10.1056/NEJM19870604316 2301

6. Effect of Enalapril on Mortality and the Development of Heart Failure in Asymptomatic Patients with Reduced Left Ventricular Ejection Fractions. New EnglandJournal ofMedicine. 1992; 327 (10): 685-91. DOI: 10.1056/NEJM199209033271003

7. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation. 1994; 90 (4): 1765-73.

8. Luttik M.L.A., Jaarsma T., van Geel P.P., Brons M., Hillege H.L., Hoes A.W. et al. Long-term follow-up in optimally treated and stable heart failure patients: primary care vs. heart failure clinic. Results of the COACH-2 study: Long-term follow-up in optimally treated and stable HF patients. European Journal of Heart Failure. 2014; 16 (11): 1241-8. DOI: 10.1002/ejhf.173

9. Swedberg K., Komajda M., Böhm M., Borer J.S., Ford I., Dubost-Brama A. et al. Ivabradine and outcomes in chronic heart failure (SHIFT ): a randomised placebo-controlled study. The Lancet. 2010; 376 (9744): 875-85. DOI: 10.1016/S0140-6736(10)61198-1

10. Pfeffer M.A., Swedberg K., Granger C.B., Held P., McMurray J.J.V., Michelson E.L. et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003; 362 (9386): 759-66.

11. Jolly K., Taylor R.S., Lip G.Y.H., Davies M., Davis R., Mant J. et al. A randomized trial of the addition of home-based exercise to specialist heart failure nurse care: the Birmingham Rehabilitation Uptake Maximisation study for patients with Congestive Heart Failure (BRUM-CHF) study. EuropeanJournal of Heart Failure. 2009; 11 (2): 205-13. DOI: 10.1093/eurjhf/hfn029

12. Flynn K.E., Pina I.L., Whellan D.J., Lin L., Blumenthal J.A., Ellis S.J. et al. Effects ofexercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009; 301 (14): 1451-9. DOI: 10.1001/jama.2009.457

13. Поляков Д.С., Фомин И.В., Валикулова Ф.Ю., Вайсберг А.Р., Краием Н., Бадин Ю.В., и др. Эпидемиологическая программа ЭПОХА-ХСН: декомпенсация ХСН в реальной клинической практике (ЭПОХА - Д - ХСН). Журнал Сердечная Недостаточность. 2016; 17 (5): 299-305

14. Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т., Фомин И.В., Бадин Ю.В., Поляков Д. С. и др. Истинная распространенность ХСН в Европейской части Российской Федерации (исследование ЭПОХА, госпитальный этап). Журнал Сердечная Недостаточность. 2011; 12 (2): 63-8

15. еленков Ю.Н., Мареев В.Ю., Агеев Ф.Т., Фомин И.В., Бадин Ю.В., Поляков Д.С. и др. Современный образ пациента с ХСН в Европейской части Российской Федерации (госпитальный этап). Журнал Сердечная Недостаточность. 2011; 12 (5): 255 9

16. Фомин И.В. Хроническая СН в Российской Федерации: что сегодня мы знаем и что должны делать. Российский кардиологический журнал. 2016; (8): 7-13

17. Maggioni A.P., Anker S.D., Dahlström U., Filippatos G., Ponikowski P., Zannad F. et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12440 patients of the ESC Heart Failure Long-Term Registry. European Journal of Heart Failure. 2013; 15(10): 1173-84. DOI: 10.1093/eurjhf/hft134

18. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ. 2004; 328 (7433): 189-0. DOI: 10.1136/bmj.37938.645220. EE

19. Senden P.J., Sabelis L.W., Zonderland M.L., Hulzebos E.H., Bol E., Mosterd W.L. The effect of physical training on workload, upper leg muscle function and muscle areas in patients with chronic heart failure. International Journal of Cardiology. 2005; 100 (2): 293-300. DOI: 10.1016/j.ijcard.2004.10.039

20. Schou M., Gustafsson F., Videbaek L., Andersen H., Toft J., Nyvad O. et al. Adding serial N-terminal pro brain natriuretic peptide measurements to optimal clinical management in outpatients with systolic heart failure: a multicentre randomized clinical trial (NorthStar monitoring study). European Journal of Heart Failure. 2013; 15 (7): 818-27. DOI: 10.1093/eurjhf/hft037

21. Santaguida P.L., Don-Wauchope A.C., Oremus M., McKelvie R., Ali U., Hill S.A. et al. BNP and NT-proBNP as prognostic markers in persons with acute decompensated heart failure: a systematic review. Heart Failure Reviews. 2014; 19 (4): 453-70. DOI: 10.1007/s10741-014-9442-y

22. Lynga P., Persson H., Hägg-Martinell A., Hägglund E., Hagerman I., Langius-Eklöf A. et al. Weight monitoring in patients with severe heart failure (WISH). A randomized controlled trial. Eur J Heart Fail. 2012; 14 (4): 438-44.DOI: 10.1093/eurjhf/hfs023

23. Faris R.F., Flather M., Purcell H., Poole-Wilson P.A., Coats A.J. Diuretics for heart failure. The Cochrane Collaboration, редактор. Cochrane Database of Systematic Reviews [Интернет]. -Chichester, UK: John Wiley & Sons, Ltd; 2012фев15 [цитируется по 8 март 2018 г.].

24. Faris R., Flather M., Purcell H., Henein M., Poole-Wilson P., Coats A. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. Int J Cardiol. 2002; 82 (2): 149-58. PMID: 11853901

25. Lennie T.A., Song E.K., Wu J.-R., Chung M.L., Dunbar S.B., Pressler S.J. et al. Three gram sodium intake is associated with longer event-free survival only in patients with advanced heart failure.J ournal of Cardiac Failure. 2011; 17 (4): 325-30. DOI: 10.1016/j.cardfail. 2010.11.008

26. Arcand J., Ivanov J., Sasson A., Floras V., Al-Hesayen A., Azevedo E.R. et al. A high-sodium diet is associated with acute decompensated heart failure in ambulatory heart failure patients: a prospective follow-up study. The American Journal of Clinical Nutrition. 2011; 93 (2): 332-DOI: 10.3945/ajcn. 110.000174

27. Swedberg K/, Kjekshus J/, Snapinn S. Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I. Eur Heart J. 1999; 20 (2): 136-9.

28. Арутюнов А.Г., Драгунов Д.О., Арутюнов Г.П., Рылова А.К., Пашкевич Д.Д., Витер К.В. et al. Первое открытое исследование синдрома острой декомпенсации СН и сопутствующих заболеваний в Российской Федерации. Независимый регистр ОРАКУЛ-РФ. Кардиология. 2015; 55 (5): 12-21.

29. Work Group Membership. Kidney International Supplements. 2012; 2 (1): 2. DOI: 10.1038/kisup.2012.2

30. Поляков Д.С., Фомин И.В., Вайсберг А.Р., Валикулова Ф.Ю. Оценка влияния острого повреждения почек на прогноз у пациентов с острой декомпенсацией СН в условиях клинической практики. Кардиология. 2016; 56 (12): 40-7.

31. Ambrosy A.P., Vaduganathan M., Huffman M.D., Khan S., Kwasny M.J., Fought A.J. et al. Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial. European Journal of Heart Failure. 2012; 14 (3): 302-11. DOI: 10.1093/eurjhf/hfs007

32. Арутюнов А.Г., Рылова А.К., Арутюнов Г.П. Регистр госпитализированных пациентов с декомпенсацией кровообращения (Павловский регистр). Сообщение 1. Современная клиническая характеристика пациента с декомпенсацией кровообращения. Клинические фенотипы пациентов. Журнал Сердечная Недостаточность. 2014; 15 (1): 23-32.

33. Jankowska E.A., Malyszko J., Ardehali H., Koc-Zorawska E., Banasiak W., von Haehling S. et al. Iron status in patients with chronic heart failure. European Heart Journal. 2013; 34 (11): 827-34. DOI: 10.1093/eur-heartj/ehs377

34. Cleland J.G.F., Massie B.M., Packer M. Sudden death in heart failure: vascular or electrical? EuropeanJournal of Heart Failure. 1999; 1 (1): 41-DOI: 10.1016/S1388-9842 (99) 00009-4

35. Pitt B., Collins A.J., Reaven N., Funk S., Bakris G.L., Bushinsky D.A. Abstract 13320: Effect of Cardiovascular Comorbidities on the Mortality Risk Associated with Serum Potassium. Circulation. 2014; 130 (Suppl 2): A13320 - A13320.

36. McAlister F.A. Meta-analysis: ß-blocker dose, heart rate reduction, and death in patients with heart failure. Annals of Internal Medicine. 2009; 150 (11) : 784. DOI: 10.7326/0003-4819-150-11-200906020-00006

37. Lonn E. Dose response of ACE inhibitors: implications of the SECURE trial. Curr Control Trials Cardiovasc Med. 2001; 2 (4): 155-9.

38. Maggioni A.P., Dahlström U., Filippatos G., Chioncel O., Crespo Leiro M., Drozdz J. et al. EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2013; 15 (7): 808-17. DOI: 10.1093/eurjhf/hft050